BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

被引：0
|
作者：
Kim, D.
Saglio, G.
Martinelli, G.
Shou, Y.
Stein, A. M.
Woodman, R. C.
Kantarjian, H.
Hughes, T. P.
Radich, J. P.
Hochhaus, A.
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[2] Univ Turin, San Luigi Gonzaga Hosp, Orbassano, Italy
[3] Inst Hematol, Bologna, Italy
[4] Novartis Inst BioMed Res, Cambridge, MA USA
[5] Novartis Pharmaceut, Cambridge, MA USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] SA Pathol, Dept Haematol, Adelaide, SA, Australia
[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[10] Univ Klinikum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6567
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES
    Saglio, S.
    Hughes, T.
    Kim, D. W.
    Hanfstein, B.
    Gottardi, E.
    Branford, S.
    Goh, H.
    Beppu, L.
    Soverini, S.
    Shou, Y.
    Stein, A.
    Woodman, R.
    Kantarjian, H.
    Radich, J.
    Hochhaus, A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 342 - 343
  • [2] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Hochhaus, A.
    Saglio, A.
    Kantarjian, H.
    Haque, A.
    Shou, Y.
    Woodman, R. C.
    Hughes, T. P.
    Radich, J. P.
    Martinelli, G.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [4] RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB
    Stein, A.
    Shou, Y.
    Bottino, D.
    Chia, Y. L.
    Woodman, R.
    Martinelli, G.
    Hughes, T.
    Mueller, M.
    Beppu, L.
    Gottardi, E.
    Branford, S.
    Soverini, S.
    Goh, H.
    Hochhaus, A.
    Kim, D.
    Saglio, G.
    Radich, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 56 - 56
  • [5] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [7] ANALYSIS OF BCR-ABL MUTATIONS IN MEXICAN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH plus CML) TREATED WITH NILOTINIB
    Ayala, J. L.
    Hurtado, R.
    Delgado, N.
    Vargas, P.
    Meillon, L.
    Tapia, N.
    Alvarado, M.
    De Diego, J.
    Azaola, P.
    Gonzalez, M.
    Lugo, Y.
    Hernandez, R.
    Kassack, J. J.
    Cleto, S.
    Nambo, M.
    Reyes, G.
    Cantu, O.
    Aguayo, A.
    Mucius, I.
    Herrera, A.
    Nacho, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 220 - 220
  • [8] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [9] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [10] BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
12345